Morning Briefing
Summaries of health policy coverage from major news organizations
Johnson & Johnson Invests $50M In Tesaro, Licenses Prostate Cancer Treatment
The Wall Street Journal: Johnson & Johnson To Develop Tesaro’s Drug For Prostate Cancer
Johnson & Johnson on Wednesday said it will invest $50 million in Tesaro Inc. and license a potential prostate cancer treatment from the pharmaceutical company. Johnson’s Janssen Biotech Inc. will develop and commercialize Tesaro’s Niraparib for treatment of prostate cancer. Niraparib is an oral, once-daily treatment that is currently in late-stage clinical trails for use in ovarian and breast cancer. (Hufford, 4/6)
The Wall Street Journal: Drug For Rare Disorder Linked To Reducing Cholesterol Plaque
Cyclodextrin, a compound now in testing to treat a very rare genetic disease, may have a potential use in treating a much more common condition too: heart disease. Researchers reported Wednesday in Science Translational Medicine that in mice, cyclodextrin was able to reduce plaque and dissolve cholesterol crystals, which some research suggests could play a role in atherosclerosis, or narrowing of the arteries. (Dockser Marcus, 4/6)
